We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India. It also provides pharmaceutical products, such as prescription products primarily for cardiology, oncology, gynecology, diabetes, hematology, and ophthalmology; and diagnostic imaging equipment and other contrast agents, including computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illness, as well as sells and distributes hybrid seeds. It also exports its products. The company was incorporated in 1958 and is based in Thane, India.
TODAY'S HIGH
5135
TODAY'S LOW
4982
52 WEEK HIGH
6130
52 WEEK LOW
4218.05
% of Shares Held by
All Insider
72.72%
% of Shares Held by
Institutions
13.71%
% of Float Held by
Institutions
50.26%
Number of Institutions
Holding Shares
51
MARKET CAP
22811.03 Cr.
ETERPRISE VALUE
21768.35 Cr.
NO. OF SHARES
4.49 Cr.
BOOK VALUE
561.562
DIV. YIELD
125%
DEBT
86.40 Cr.
GROSS PROFIT
2070.20 Cr.
CASH
825.89 Cr.
REVENUE
4734.40 Cr.
REVENUE/SHARE
1053.41
Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|
Investments | 23.10 Cr. | -1.10 Cr. | -40 Cr. | -396 Cr. |
Change To Liabilities | -9.70 Cr. | 355.80 Cr. | -169.10 Cr. | 250.30 Cr. |
Total cashflows from Investing Activities | 64.20 Cr. | 6.70 Cr. | -28.90 Cr. | -414.70 Cr. |
Net Borrowings | -26.30 Cr. | -37 Cr. | -22.80 Cr. | -22.80 Cr. |
Total Cash from Financing Activities | -703.30 Cr. | -555.80 Cr. | -148.30 Cr. | -158.30 Cr. |
Other Liabilities | 96.20 Cr. | 70.20 Cr. | 53.30 Cr. | -43.10 Cr. |
Total Assets | 0 | 0 | 0 | 0 |
Net Income | 645.30 Cr. | 493.10 Cr. | 474.50 Cr. | 337.10 Cr. |
Change in Cash | -423.60 Cr. | 137.60 Cr. | 488.70 Cr. | -140.20 Cr. |
Effect of Exchange Rate | 0 | 0 | 0 | 0 |
Total Cash from Operating Activities | 215.50 Cr. | 686.70 Cr. | 665.90 Cr. | 432.80 Cr. |
Depreciation | 64.50 Cr. | 73 Cr. | 63.70 Cr. | 41.20 Cr. |
Other Cashflows from Investing Activities | 27 Cr. | 39 Cr. | 39 Cr. | 35.80 Cr. |
Dividends Paid | -672.80 Cr. | -516 Cr. | -101.50 Cr. | -126.10 Cr. |
Change to Inventory | -236.40 Cr. | -395.60 Cr. | 164.40 Cr. | -288.70 Cr. |
Change to Account Receivables | -256.30 Cr. | -37.80 Cr. | -20.50 Cr. | 171.70 Cr. |
Other Cashflows from Financing Activities | -4.20 Cr. | -2.80 Cr. | -24 Cr. | -32.20 Cr. |
Change to Net Income | -88.10 Cr. | 127.50 Cr. | 98 Cr. | -38.30 Cr. |
Capital Expenditures | -55.40 Cr. | -42 Cr. | -41.30 Cr. | -60.20 Cr. |
Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|
Research Development | None | None | None | None |
Effect of Accounting Charges | None | None | None | None |
Income Before Tax | 846.80 Cr. | 794.50 Cr. | 583.10 Cr. | 480 Cr. |
Minority Interest | None | None | None | None |
Net Income | 746.60 Cr. | 738.50 Cr. | 662.20 Cr. | 469.10 Cr. |
Selling General Administrative | 463.10 Cr. | 572.60 Cr. | 572.90 Cr. | 601 Cr. |
Gross Profit | 2070.20 Cr. | 1799.40 Cr. | 1682.90 Cr. | 1497.50 Cr. |
Ebit | 746.60 Cr. | 738.50 Cr. | 662.20 Cr. | 469.10 Cr. |
Operating Income | 746.60 Cr. | 738.50 Cr. | 662.20 Cr. | 469.10 Cr. |
Other Operating Expenses | 796 Cr. | 414.80 Cr. | 382.50 Cr. | 383.60 Cr. |
Interest Expense | -12.90 Cr. | -11 Cr. | -12.60 Cr. | -9.80 Cr. |
Extraordinary Items | None | None | None | None |
Non Recurring | None | None | None | None |
Other Items | None | None | None | None |
Income Tax Expense | 201.50 Cr. | 301.40 Cr. | 108.60 Cr. | 142.90 Cr. |
Total Revenue | 4734.40 Cr. | 4261.30 Cr. | 3609.40 Cr. | 3175.40 Cr. |
Total Operating Expenses | 3987.80 Cr. | 3522.80 Cr. | 2947.20 Cr. | 2706.30 Cr. |
Cost of Revenue | 2664.20 Cr. | 2461.90 Cr. | 1926.50 Cr. | 1677.90 Cr. |
Total Other Income Expense Net | 100.20 Cr. | 56 Cr. | -79.10 Cr. | 10.90 Cr. |
Discontinued Operations | None | None | None | None |
Net Income from Continuous Ops. | 645.30 Cr. | 493.10 Cr. | 474.50 Cr. | 337.10 Cr. |
Net Income Applicable to Common Shares | 645.30 Cr. | 493.10 Cr. | 474.50 Cr. | 337.10 Cr. |
Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
---|---|---|---|---|
Intangible Assets | 89.30 Cr. | 70.20 Cr. | 54 Cr. | 42.60 Cr. |
Capital Surplus | 0 | 139.40 Cr. | 139.40 Cr. | 139.40 Cr. |
Total Liabilities | 1828.60 Cr. | 1689 Cr. | 1263.20 Cr. | 1309.80 Cr. |
Stock Holder Equity | 2524.30 Cr. | 2550.30 Cr. | 2572.50 Cr. | 2239.40 Cr. |
Minority Interest | 0 | 0 | 0 | 0 |
Other Liabilities | 804.90 Cr. | 644.60 Cr. | 526.10 Cr. | 453.60 Cr. |
Total Assets | 4352.90 Cr. | 4239.30 Cr. | 3835.70 Cr. | 3549.20 Cr. |
Common Stock | 44.90 Cr. | 44.90 Cr. | 44.90 Cr. | 34.30 Cr. |
Retained Earnings | 0 | 2360.80 Cr. | 2383 Cr. | 2049.90 Cr. |
Other Liabilities | 117.50 Cr. | 104.30 Cr. | 110 Cr. | 121.90 Cr. |
Good Will | 0 | 0 | 0 | 0 |
Treasury Stock | 2479.40 Cr. | 5.20 Cr. | 5.20 Cr. | 15.80 Cr. |
Other Assets | 237.70 Cr. | 224.40 Cr. | 327.40 Cr. | 312.90 Cr. |
Cash | 787.40 Cr. | 1204.50 Cr. | 1066.90 Cr. | 578.20 Cr. |
Current Liabilities | 1659.30 Cr. | 1570.60 Cr. | 1139.40 Cr. | 1187.90 Cr. |
Long Term Asset Charges | 7.30 Cr. | 17.90 Cr. | 27 Cr. | 8.90 Cr. |
Short Long Term Debt | 0 | 0 | 0 | 0 |
Other Stockholder Equity | 2479.40 Cr. | 5.20 Cr. | 5.20 Cr. | 15.80 Cr. |
Property Plant Equipment | 450.40 Cr. | 400.80 Cr. | 439.90 Cr. | 413.90 Cr. |
Total Cur. Assets | 3575.50 Cr. | 3543.90 Cr. | 3014.40 Cr. | 2779.80 Cr. |
Long Term Investments | 0 | 0 | 0 | 0 |
Net Tangible Assets | 2435 Cr. | 2480.10 Cr. | 2518.50 Cr. | 2196.80 Cr. |
Short Term Investments | 38.50 Cr. | 0 | 0 | 0 |
Net Receivables | 1004.70 Cr. | 763.80 Cr. | 740.40 Cr. | 755.90 Cr. |
Long Term Debt | 0 | 0 | 0 | 0 |
Inventory | 1512 Cr. | 1325.10 Cr. | 963.50 Cr. | 1157 Cr. |
Accounts Payable | 819.80 Cr. | 830.30 Cr. | 474.90 Cr. | 644.20 Cr. |